Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26480044 | 1.00 | TSHR (0.33) | TSHRELANE | |
| SCHEMBL20152007 | 0.95 | TSHR (0.31) | TSHR | |
| SCHEMBL13254040 | 0.87 | — | — | |
| SCHEMBL23685209 | 0.84 | TP53 (0.35) | TSHR | |
| SCHEMBL13991009 | 0.84 | TP53 (0.35) | TSHR | |
| SCHEMBL15038273 | 0.84 | TP53 (0.35) | TSHR | |
| SCHEMBL13991011 | 0.84 | TP53 (0.35) | TSHR | |
| SCHEMBL27342199 | 0.82 | CA12 (0.30) | — | |
| SCHEMBL24437427 | 0.82 | CA12 (0.30) | — | |
| SCHEMBL13991006 | 0.80 | TSHR (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-11-02 | — | — | US | disclosed |
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2023-05-09 | — | — | US | disclosed |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120077047-A1 | Antistatic hardcoat layer-forming composition, optical film, production method of optical film, polarizing plate and image display device | FUJIFILM CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120077046-A1 | Composition for forming hardcoat layer, optical film, method of producing optical film, polarizing plate and image display device | FUJIFILM CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120075706-A1 | Optical film having antistatic layer, antireflection film, polarizing plate and image display device | FUJIFILM CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20110242654-A1 | Hardcoat layer-forming composition, optical film, production method of optical film, polarizing plate and image display device | FUJIFILM CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110183110-A1 | Optical film, antireflection film, polarizing plate and image display apparatus | FUJIFILM CORPORATION (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-20100246014-A1 | ANTIREFLECTIVE FILM, POLARIZING PLATE, IMAGE DISPLAY DEVICE AND COATING COMPOSITION FOR FORMING LOW REFRACTIVE INDEX LAYER | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | TSHR 3611/4885ELANE 2437/4885 |
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | SERPINB1, KLKB1, MPO | TSHR 2435/4885ELANE 6/4885 |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | TSHR 3582/4885ELANE 2990/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | TSHR 3582/4885ELANE 2990/4885 |
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | SERPINB1, KLKB1, MPO | TSHR 2435/4885ELANE 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.